Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
BRISBANE, Calif., Aug. 11, 2017 -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that Cameron Durrant, MD, chairman and CEO, has been named a PharmaVOICE 100 Red Jacket Award honoree as part of the annual PharmaVOICE 100.
The PharmaVOICE 100 Red Jacket Award is a prestigious annual distinction that serves as a ‘hall of fame’ for executives who have been recognized multiple times in the PharmaVOICE 100, the publication’s annual list of inspiring industry leaders. PharmaVOICE 100 Red Jacket Award winners are selected as individuals who have shown a new kind of leadership, such as driving new ways of thinking, acting and leading; creating new opportunities from the ‘impossible’; having persistence of vision; and inspiring leaders for today and tomorrow.
“I am honored and grateful to be inducted into such an influential circle of leaders as the PharmaVOICE 100 Red Jacket Award,” said Dr. Durrant. “Finding new ways forward requires the persistence and resilience to execute and deliver them. This honor reflects the determination and forward-thinking mindset of our talented team at Humanigen, as we continue to execute on our priorities to help neglected and rare disease patients.”
Since January 2016, Dr. Durrant has led the transformation of Humanigen through significant operational, reputational and legal hurdles. Dr. Durrant is a five-time PharmaVOICE 100 honoree. To read the 2017 PharmaVOICE 100 Red Jacket Award profiles, visit www.pharmavoice.com.
About Humanigen
Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). For more information, visit www.humanigen.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
